AAQL — Antiaging Quantum Living Income Statement
0.000.00%
- $17.73m
- $18.97m
- $0.82m
Annual income statement for Antiaging Quantum Living, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.004 | 0.007 | 0.014 | 0.007 | 0.818 |
| Cost of Revenue | |||||
| Gross Profit | 0.003 | 0.006 | 0.014 | 0.007 | 0.429 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 0.077 | 0.052 | 0.05 | 0.421 | 1.61 |
| Operating Profit | -0.073 | -0.045 | -0.037 | -0.413 | -0.79 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.067 | -0.043 | -0.037 | -0.413 | -0.72 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.067 | -0.043 | -0.037 | -0.413 | -0.72 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.067 | -0.043 | -0.037 | -0.413 | -0.72 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.067 | -0.043 | -0.037 | -0.413 | -0.72 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.001 | -0.001 | -0.014 | -0.024 |